M. Candelaria Et Al. , "Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study," LEUKEMIA & LYMPHOMA , vol.60, no.14, pp.3375-3385, 2019
Candelaria, M. Et Al. 2019. Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. LEUKEMIA & LYMPHOMA , vol.60, no.14 , 3375-3385.
Candelaria, M., Gonzalez, D. E., Delamain, M. T., Bar, D. O., Beniwal, S. K., Dasappa, L., ... Flores, D. H.(2019). Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. LEUKEMIA & LYMPHOMA , vol.60, no.14, 3375-3385.
Candelaria, Myrna Et Al. "Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study," LEUKEMIA & LYMPHOMA , vol.60, no.14, 3375-3385, 2019
Candelaria, Myrna Et Al. "Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study." LEUKEMIA & LYMPHOMA , vol.60, no.14, pp.3375-3385, 2019
Candelaria, M. Et Al. (2019) . "Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study." LEUKEMIA & LYMPHOMA , vol.60, no.14, pp.3375-3385.
@article{article, author={Myrna Candelaria Et Al. }, title={Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study}, journal={LEUKEMIA & LYMPHOMA}, year=2019, pages={3375-3385} }